A Herpes Simplex Virus Type 1 γ34.5 Second-Site Suppressor Mutant That Exhibits Enhanced Growth in Cultured Glioblastoma Cells Is Severely Attenuated in Animals
Open Access
- 1 June 2001
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (11), 5189-5196
- https://doi.org/10.1128/jvi.75.11.5189-5196.2001
Abstract
We describe here the neurovirulence properties of a herpes simplex virus type 1 γ34.5 second-site suppressor mutant. γ34.5 mutants are nonneurovirulent in animals and fail to grow in a variety of cultured cells due to a block at the level of protein synthesis. Extragenic suppressors with restored capacity to replicate in cells that normally do not support the growth of the parental γ34.5 deletion mutant have been isolated. Although the suppressor virus reacquires the ability to grow in nonpermissive cultured cells, it remains severely attenuated in mice and is indistinguishable from the mutant γ34.5 parent virus at the doses investigated. Repairing the γ34.5 mutation in the suppressor mutant restores neurovirulence to wild-type levels. These studies illustrate that (i) the protein synthesis and neurovirulence defects observed in γ34.5 mutant viruses can be genetically separated by an extragenic mutation at another site in the viral chromosome; (ii) the extragenic suppressor mutation does not affect neurovirulence; and (iii) the attenuated γ34.5 mutant, which replicates poorly in many cell types, can be modified by genetic selection to generate a nonpathogenic variant that regains the ability to grow robustly in a nonpermissive glioblastoma cell line. As this γ34.5 second-site suppressor variant is attenuated and replicates vigorously in neoplastic cells, it may have potential as a replication-competent, viral antitumor agent.Keywords
This publication has 52 references indexed in Scilit:
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Conditionally replicating herpes vectors for cancer therapyJournal of Clinical Investigation, 2000
- Herpes Simplex Virus as an in Situ Cancer Vaccine for the Induction of Specific Anti-Tumor ImmunityHuman Gene Therapy, 1999
- Herpes simplex virus turns off the TAP to evade host immunityNature, 1995
- Selective Destruction of Gliomas in Immunocompetent Rats by Thymidine Kinase-Defective Herpes Simplex Virus Type 1JNCI Journal of the National Cancer Institute, 1994
- Mutant herpes simplex virus induced regression of tumors growing in immunocompetent ratsJournal of Neuro-Oncology, 1994
- Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to AcyclovirNeurosurgery, 1993
- Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with Attenuated Herpes Simplex Mutants that Retain Susceptibility to AcyclovirNeurosurgery, 1993
- Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequenceJournal of General Virology, 1991
- Mapping of Herpes Simplex Virus-1 Neurovirulence to γ 1 34.5, a Gene Nonessential for Growth in CultureScience, 1990